SignalCorporate
FTC wants Martin Shkreli held in contempt for trading pharma stocks
FTC wants Martin Shkreli held in contempt for trading pharma stocks
Context
What happened: The FTC asked a federal judge to hold Martin Shkreli in contempt for allegedly violating a 2022 court order by trading pharma stocks and posting opinions about pharma companies.
Key numbers: At least 60 pharma stocks traded; lifetime ban issued February 2022; released from prison May 2022; trading phases since July 2022; June 2026 challenge with $10M; Daraprim price raised to $750 per pill from $13.50; convicted 2017; seven years in prison
Why it matters: The FTC is seeking divestment of his pharma stocks, a fine equal to his profits, and consequences for future violations.
Market: +2.1% by next close ($323.07 on Oct 14), +12.7% YTD
Coverage: 10 outlets in 24h
What changed
The FTC asked a federal judge to hold Martin Shkreli in contempt for allegedly violating a 2022 court order by trading pharma stocks and posting opinions about pharma companies.
Why it matters
The FTC is seeking divestment of his pharma stocks, a fine equal to his profits, and consequences for future violations.
Market: +2.1% by next close ($323.07 on Oct 14), +12.7% YTD